skip to Main Content

News archive

Making progress and keeping steady!
The recording of our CEO Dorte X. Gram’s presentation (in Swedish) from Aktiespararna is now live.
Please, find the link to the video (in Swedish) here
(15-March-2022)
Our CEO Dorte X. Gram presented our status yesterday evening including the progress with more FTE’s and API in the making
Please, find the link to the video (in English) here
(05-March-2022)
We’re very honoured that PILA PHARMA is a final nominee for the 2022 Malmö Business Award within Life Science!
(04-March-2022)
Good summary of our progress as reported in our quarterly report plus comments from our CEO Dorte X. Gram
 
Vänligen läs artikeln (in Swedish) här


Please, read the article (in English) here

(03-March-2022)
We’re pleased to share this quarterly report interview with our CEO Dorte X. Gram, on our good progress. It was recorded last week when we visited some of our UK-collaborators, here, Quay Pharma in north Wales, that recently manufactured new tablets for us for use in clinical trials!


Please, find the link to the video (in English) here

(02-March-2022)
Pila Pharma Press releases
PILA PHARMA AB – VD Dorte X. Gram ökar sitt innehav
Läs pressmeddelandet (in Swedish) här

 

PHARMA AB – CEO Dorte X. Gram increases share holding
Read the press release (in English) here

(25-February-2022)

PILA PHARMA bokslutskommuniké för 1 januari – 31 december 2021
Läs rapporten PDF (in Swedish) här

(18-February-2022)
Pila Pharma Press releases
PILA PHARMA bokslutskommuniké för 1 januari – 31 december 2021
Läs pressmeddelandet (in Swedish) här

 

PILA PHARMA publishes year-end report January 1 – December 31, 2021
Read the press release (in English) here

(18-February-2022)
Halsa Forskning Cover
Last week, our CEO Dorte X. Gram appeared in this issue of Hälsa & Forskning distributed with Svenska Dagbladet.
Please, read the article (in Swedish) here
(07-February-2022)
Pila Pharma Press releases

PILA PHARMA AB tillkännager milstolpe avseende API-produktion samt ändringar i organisationen
Läs pressmeddelandet (in Swedish) här

PILA PHARMA AB, announces API manufacturing milestone achieved and changes to organisation
Read the press release (in English) here

(04-February-2022)
Happy New Year! We’re back and looking toward an eventful 2022! 😃 
Biostock has written a small summary of us and our milestones for the coming year.
Find the links below! 😃
(SWE) here
(ENG) here
(19-January-2022)
On Friday our CEO Dorte X. Gram went for a film and photo shoot here at Malmö Live Konserthus
We can’t yet disclose what for so stay tuned 🤗
(17-January-2022)
Redeye this morning published their analysis of our business case.
Please, have a look if you need guidance on assessing our risks and the overall (investment) potential (in English) here
(17-December-2021)
Last pitch of the year was done yesterday our CEO Dorte X. Gram at Redeye
Please, find the link to the video (in Swedish) here
(17-December-2021)
Earlier today, our CEO Dorte X. Gram was interviewed by Aktier.
We thank for the invitation and many good questions!
Please, find interview in Swedish (start at time 4:19) here
(10-December-2021)
Please, check out this PILA PHARMA ’hisspitch’ that Aktiespararna made last week when our CEO Dorte X. Gram was in Stockholm.
Please, find the link to the video (in English) here
(10-December-2021)
Dr. Julius, yesterday, gave his Nobel prize lecture on the discovery of ’the chili receptor’ TRPV1 and its role in thermo-sensation and pain. Our diabetes drug candidate is a TRPV1-antagonist.
Please, find the link to the video (in English) here
(08-December-2021)
In case you missed it, our CEO’s presentation from today’s event at Aktiespararna is now online
Please, find the link to our CEOs presentation (in English) here
(02-December-2021)
Tomorrow, December 2nd at 11:30 AM, our CEO Dorte X. Gram will be presenting at Aktiespararnas “Stora Aktiedagen” in Stockholm, and, give an update on #PILA PHARMA.
It’s possible to text your questions to +46 (0)79-347 98 45 or email to event@aktiespararna.se for the moderator will handle the questions during the Q&A.
You can follow the live stream here (in English) here
(01-December-2021)
We’re delighted to announce that we have signed an agreement with ERBC (European Research Biology Center) on the conduct of our planned preclinical safety studies.
We look forward to the collaboration and, even more so, the results!
Read the full article (in English) here

Läs hela artikeln (in Swedish) här

(01-December-2021)
Pila Pharma Press releases

PILA PHARMA AB skriver avtal med den prekliniska tjänstleveranören ERBC
Läs pressmeddelandet (in Swedish) här

PILA PHARMA AB, announces ink of agreement with pre-clinical service provider ERBC
Read the press release (in English) here

(26-November-2021)
Last Sunday, Politiken, had an appendix on Diabetes and we appeared on the cover and in a nice article on p. 8-9
Read the article (in Danish) here
(23-November-2021)
We participated in the Redeye Life Science Day 2021 on Thursday last week
Please, find the link to our CEOs presentation (in English) here
(19-November-2021)
FYI our CEO increased the stock holding in PILA earlier this week. Biostock commented on the transaction
You can read it in English here
You can read it in Swedish here
(19-November-2021)
Politiken Pila Pharma
Our CEO was on the cover(again) in one of Politikens appendices on Life Sciences published last Friday
Read the article (in Danish) here
(19-November-2021)
We’re pleased to share our CEOs presentation (in Danish) last week
Thank you to Økonomisk Ugebrev Lifescience for inviting us!
Watch the video in (in Danish) here
(19-November-2021)
Pila Pharma Press releases

PILA PHARMA AB – VD Dorte X. Gram ökar sitt innehav

Läs pressmeddelandet (in Swedish) här

PHARMA AB – CEO Dorte X. Gram increases share holding

Read the press release (in English) here

(16-November-2021)
We’re pleased to share that our CEO Dorte X. Gram will present PILA PHARMA in Stockholm on Thursday 11 November at 16:30 at the Redeye Lifescience day 2021!
you’re invited to join! Sing up via the link here
(05-November-2021)
Biostock has written an update on us after our Q3 report release
You can read it in English here
(05-November-2021)
Save the date (10 Nov 2021): our CEO Dorte X. Gram will be presenting in Copenhagen, Denmark
you’re invited to join! Sing up via the link here
(02-November-2021)

Delårsrapport 1 juli – 30 september 2021

Läs läs rapporten PDF (in Swedish) här

(26-October-2021)
Pila Pharma Press releases

PILA PHARMA offentliggör delårsrapport för 1 juli – 30 september 2021

Läs pressmeddelandet (in Swedish) här
Läs pressmeddelandet PDF (in Swedish) här

PILA PHARMA publishes interim report for July 1 – September 30, 2021

Read the press release (in English) here
Read the Press release PDF (in English) here

(26-October-2021)
Pila Pharma Press releases

Nobelpris till upptäckten av PILA PHARMA:s ledande princip
Läs pressmeddelandet (in Swedish) här
Läs pressmeddelandet PDF (in Swedish) här

Nobel prize for the discovery of PILA PHARMA’s leading principle
Read the press release (in English) here
Read the Press release PDF (in English) here

(05-October-2021)

Yesterday, our CEO Dorte X. Gram presented our company at Aktiespararna.

Please find a link to the presentation here

(29-September-2021)
BioStock

BioStocks: “Pila Pharma takes final steps before toxicology studies”
Read the full article (in English) here

BioStocks: “Pila Pharma tar sista stegen innan toxikologiska studier”
Läs hela artikeln (in Swedish) här

(22-September-2021)
Pila Pharma Press releases

PILA PHARMA erhåller GMP-certifiering av placebo-tabletter
Läs pressmeddelandet (in Swedish) här
Läs pressmeddelandet PDF (in Swedish) här

PILA PHARMA recieves GMP certification of placebo tablets
Read the press release (in English) here
Read the Press release PDF (in English) here

(14-September-2021)
Life Science

Our COO, Lars Bukhave Rasmussen (and possibly som other PILAs), will be attending “The Future of Swedish & Danish Life Science” meeting in Lund, Sweden September 2nd 2021.

Read more (in English) here

(26-August-2021)
Pila Pharma Press releases

PILA PHARMA AB tecknar tillverkningsavtal om API

Läs pressmeddelandet (in Swedish) här
Läs pressmeddelandet PDF (in Swedish) here

Read the press release (in English) here
Read the Press release PDF (in English) here

(05-August-2021)
On Friday, our CEO was interviewed about PILA PHARMA ABs first week as listed company in the middle of summer and as one of the last companies in a row to list in on Nasdaq First North GM.
Thank you to MedWatch and Elizabeth Mønsted Johansen for writing about us!

Read more (in Danish) here

(23-July-2021)
Pila Pharma Press releases

Första dag för handel med teckningsoptioner, PILA TO 1, blir den 22 juli 2021

Läs pressmeddelandet här
Read the Press release PDF (in Swedish) here

(20-July-2021)

PILA PHARMA AB is off 🚀🌟
Our listing on Nasdaq was one ‘once in a life-time’ event and our CEO want to thank everybody involved in making it happen.

(15-July-2021)
Pila Pharma Press releases

I dag, den 15 juli 2021, är första handelsdag för PILA PHARMA på Nasdaq First North Growth Market

Läs pressmeddelandet här
Read the Press release PDF (in Swedish) here

(15-July-2021)

Today, at 9 am CET the PILA PHARMA team will be ringing the bell – follow us live here

(15-July-2021)

Very pleased that Nasdaq last week gave PILA PHARMA AB the final approval for the list. We look forward to ‘first trading day’ on Thursday 15 July 2021.
For your information, our ‘ticker’ ‘PILA’

Read more (in English) here

(08-July-2021)
Pila Pharma Press releases

PILA PHARMA AB (publ) nyemission blev fulltecknad – handel på Nasdaq First North Growth Market planeras starta den omkring 15 juli 2021

Läs pressmeddelandet här
Read the Press release PDF (in Swedish) here

(05-July-2021)

On 16 June, Børsen published this well-written article on PILA PHARMA AB by Kevin Grønnemann commented by Senior Equity Analyst Søren Løntoft Hansen at Sydbank. I was pleased to see, that Søren, believe ‘it can be done’! With Sørens permission, I’m pleased to share an English summary of his statements: “Even though it will not be an easy task, I think that a compound that effectively lowers blood glucose, has a good safety profile and perhaps addresses some of the co-morbidities of diabetes as cardio-vascular disease, can be made. If, on top, the compound can be marketed at lower cost, then I actually believe it has potential!”. (in Danish) here

(16 june 2021)

We are so incredibly honoured to share that the American Diabetes Association(ADA) is featuring PILA PHARMA AB in the Thought Leadership Film Series, a part of ADA’s 81st Scientific Sessions program in June 2021, starting today.

In the invitation letter, it was written: We are interested in profiling Pila’s pioneering research and development in the science surrounding TPRV1 inhibition, and how regulation of this mechanism has tremendous potential to be exploited for the treatment of diabetes. The pandemic has triggered a diabetes crisis of another sort, having multiplied the complications associated with the disease and has left diabetics more vulnerable than ever before. The pandemic has further underscored the dire need for innovative approaches that go beyond the conventional realms of the diabetes field, and therefore facilitating this is the primary focus for ADA TV this year. There is substantial pre-clinical evidence indicating a role for TPRV1 in metabolic diseases, however this novel avenue has never really been pursued despite its potential. Given that Pila Pharma is one of the few organisations that is working in this innovative space, we believe that it has the potential to make an incredibly valuable addition to this year’s series, as many in the diabetes community could learn and benefit greatly from the story behind your work.”

What at great honour – it fuels us with energy and strength to overcome all challenges ahead in order to eventually provide our new type of diabetes treatment to people with diabetes in need there off!

Thank you so much to our scientific advisors Mark Evans and Jens Juul Holst for helping our CEO explain!

Watch the video in English here

(24 june 2021)

Affärsvärlden published their IPO-analysis (in Swedish) of PILA PHARMA AB. We note that they find our premoney valuation fair here

(23 june 2021)

Thank you to Millionærklubben and Pernille Enggaard for paying attention to us and for yesterdays radio-interview of our CEO. You can listen to it here (in Danish), time 19:09 to 37:5 here

(22 june 2021)

Pitching the PILA PHARMA AB investment case live for Aktiespararna
Watch the video where we explain what PILA PHARMA is about. (in Swedish) here

(21 june 2021)

Proud to be on the cover of todays LIFE SCIENCE appedix in Politiken (in Danish)
Science for Life – makes everyday life meaningful to me!

(18 june 2021)

“PILA PHARMA vill ta ett nytt grepp om diabetes”
Biostock feature article on PILA PHARMA (in Swedish) here

(18 june 2021)

Analyse the IPO Guide PILA PHARMA

Diabetes company with new treatment in sight.
Read the analysis (in Swedish) here

(21 june 2021)

“Hon går till börsen med framtidens diabetesläkemedel”
Article on PILA PHARMA AB out now on the Swedish online magazine Realtid (in Swedish)

(20 june 2021)

”PILA PHARMA AB med den tidligere Novo Nordisk-forsker Dorte X. Gram i spidsen er nu klar til at ringe med børsklokken på det svenske Nasdaq First North Growth Market i Stockholm.”

Feature article in the life science magazine MedWatch (in Danish) here

(16 june 2021)

”PILA PHARMA rustar bolaget inför en ny fas och accelererad utvecklingsresa”
Feature article in Dagens Industri appendix Invest Talks (in Swedish) here

(15 june 2021)

”Nu påbörjas resan mot framtidens diabetesläkemedel”
PILA PHARMA AB featured in an article on p. 19 in Dagens Industri appendix Hållbar Finans with focus on sustainable finance (in Swedish) here

(10 june 2021)
Pila Pharma Press releases

PILA PHARMA AB (publ) tillkännager GMP-certificering av en ny sats om 4 mg XEN-D0501-tabletter för klinisk användning

Läs pressmeddelandet här
Read the Press release PDF (in english) here

(17-juni-2021)
Pila Pharma Press releases

PILA PHARMA AB (publ) erhåller villkorat godkännande för notering på Nasdaq First North Growth Market Stockholm och offentliggör prospekt

Läs pressmeddelandet här
Read the Press release PDF (in english) here

(15-juni-2021)

This publication about DANSK BIOTEK is distributed in Denmark with todays Berlingske.

Read about on page 12-13 and about my personal view on fundraising in Denmark vs Sweden on page 20! (in Danish) here
NY PILLE SKAL FORBEDRE LIVET FOR MILLIONER AF TYPE 2-DIABETIKERE (in Danish) here
NÅR BIOTEK-SUCCES KRÆVER DET BEDSTE FRA BÅDE DANMARK OG SVERIGE (in Danish) here

(19-May-2021)

We’ve been interviewed about our background and our intentions to list PILA PHARMA AB later this year.

Please, read the article by Biostock (in Swedish) here

(23-Apr-2021)

We’re delighted to be the cover of this collection of CEO interviews!

Read the Swedish Health Care Sector Analysis distributed with Dagens Industri here
Read the article about Pila Pharma (in Swedish) here

(17-Mar-2021)

Video interview (in Swedish) with CEO Dorte X. Gram by ‘Invest Talks’

Watch the interview in Swedish here

(12-Mar-2021)

Development of a novel drug to treat diabetes.
Investor presentation by CEO Dorte X. Gram at the BioStock Life Science Summit 2020, Lund, Sweden.

Watch the presentation in English here

(17-Nov-2020)

The Malmö-based company Pila Pharma, which has a drug candidate for type 2 diabetes, will be listed on one of the Swedish stock exchanges in the second quarter of next year.

Read the article in Swedish here

(17-Nov-2020)

Pila Pharma has scheduled its arrival on the Swedish stock market for May next year with the goal of fetching SEK 50m for developing the firm’s diabetes tablet leading up to phase III.

An interview with CEO Dorte X. Gram by Medwatch, Denmark.
Read the article in English here
Read the article in Danish here

(17-Nov-2020)

Our Opinion and Concept Paper on the role of TRPV1 in diabetes published in Trends in Molecular Medicine.

Read the paper here

(November 2017)

PILA PHARMA AB has been selected to be 1 of 200 SMEs to receive an SME Instrument Phase 1 grant (EUR 50 000).

Read the general EU announcement here and the project abstract here

(20 December 2018)

Novo-forsker gjorde ph.d.-projekt til biotekselskab og forbereder nu fase 2-studie.

An interview with CEO Dorte X. Gram by Medwatch, Denmark.
Read the article in Danish here

(1 January 2019)

Om jag har rätt kan detta bli gigantisk.
An interview with CEO Dorte X. Gram by BioStock, Sweden.

Read the article in Swedish here

PILA PHARMA är klar med uppstartsfasen och flyttar ut från inkubatorn.
An interview with CEO Dorte X. Gram published by Medeon, Sweden.

Read the article in Swedish here

Pila Pharma

Nytt piller skal göra livet lättare för diabetiker – svensk bolag vill förändra sjukvården.
An interview with CEO Dorte X. Gram published in Veckans Affärer, Sweden.
Winning prize to PILA PHARMA at the Almi Invest pitch competition 2016, sponsored by Veckans Affärer.

Check out the resulting article here

Uppstickaren som vill ta plats i läkemedelsindustrin.
An interview with CEO Dorte X. Gram published in ‘DI Almedalen, Distributed with Dagens Industri, Sweden.

Read the article in Swedish here

We are proud to be on the cover of the June 2017 issue of Affärslivet Norden, Medicine and Science magazine that focuses on innovation.
The magazine was distributed with Svenska Dagbladet.

Read the article in Swedish here

Stora förhoppningar på nytt effektivt läkemedel mot diabetes typ 2.
An interview with CEO Dorte X. Gram  published in ‘Analys Öresund’, Distributed with Dagens Industri, Sweden.

Read the article in Swedish here
Read the magazine in Swedish here

“Min uppfinning kom och hämtade tillbaka mig”
Dr. Dorte X. Gram, CEO of PILA PHARMA was interviewed by Sydsvenskan, Sweden.

Read the article in Swedish here

After ten years of diabetes R&D at Novo Nordisk, Dorte X. Gram took her findings and work further to start something on her own. As founder and CEO of PILA PHARMA she hopes to bring a new oral anti-diabetic agent to the market.

Read the article here

Development of a novel drug to treat diabetes.
Investor presentation by CEO Dorte X. Gram at the BioStock Life Science Summit 2018, Lund, Sweden.

Watch the presentation in English here

(25-Oct-2018)

We’re very pleased to share PILA PHARMA AB‘s new Youtube channel.

The first film shows a guest lecture at Prague University in September 2017 where CEO Dorte X. Gram talked to students about starting up a biotech company.

Watch the video here

(04-Sep-2017)

At BioEurope Spring in Stockholm in April 2016 Dr. Dorte X. Gram, CEO of PILA PHARMA was interviewed by the organizers about the current status and our plans going forward.

Please find the links below:
partnering360.com

(08-Apr-2016)

Investor presentation at ‘Next Big Thing’ (by Blasieholmen Investment Group)
Moderna Museet, Stockholm, Sweden

Watch the presentation here
Direct link to presentation here

(02-Dec-2016)

PILA PHARMA yesterday won the title “Årets pitchare 2016” at the ALMI Invest Seed Day in Stockholm, Sweden!
The 1-min pitch competition was held amongst 17 selected out of ALMI Invests 400 portfolio companies.

(06-Dec-2016)
Comments by Dorte X. Gram

In order to maximise the chance of getting to the final, I chose to do an alternative type of pitch to describe the ALMI-PILA history as well as the content of the project (indirectly).

At the final I did ‘the usual stuff’ with market size, potential return of investment and potential exit value (potentially in the unicorn league).

I’m very proud that the audience yesterday selected me and PILA PHARMA as winner of the title ‘Årets pitchare 2016’ at the ALMI Invest Seed Day!

 

ALTERNATIVE PITCH by PILA PHARMA:

Tack Sverige för ett fantastisk inkubator och innovations system!
Tack Malmö för ett häftigt uppstarts och tillväxt miljö!
— Forza Malmö, eller hur, Per?
Tack Per Antonsson, ALMI Invest Syd, för att du inte tröttnade på min mejl-storm om min teori!
Tack Universum för att Per hade förmåga att förstå teorin och att inse hur STORT det skulle kunna bli om man kan bota diabetes genom att blokera chili-receptorn!
Tack ALMI Invest för att ni vågade satsa på min kostnads-effektiva plan om snabb klinisk bevis för min diabetes tablet – och sen exit!
Tack befintliga och kommande investerare för att ni inte bara vil tjäna masser med pengar men också vil göra något bra för samhället och vara med om att slå ihjäl det stora diabetes-monster!

Tack!

Contact us

PilaPharma

Past meetings

78th Scientific Sessions

Orlando, Florida
June 22 – 26, 2018

3rd Biotech Hanse

Stockholm, Sweden
June 14, 2018

The Future of Swedish & Danish Life Science

Lund, Sweden
March 22, 2018

Diabetes Samverkan Sverige

Malmö, Sweden
March 22, 2018

BIO-EUROPE SPRING

Amsterdam, The Netherlands
March 12-14, 2018

BOSTON BIOTECH CONFERENCE
EUROPE CEO

Amsterdam, The Netherlands
March 11, 2018

Business Sweden

French-Swedish Life Science Day 2017

Paris, France
December 14, 2017

Nordic Female Investor Meeting 2017

Malmö, Sweden
November 21, 2017

NFIM17

Nordea Markets

Copenhagen, Denmark
November 20, 2017
Nordea Markets

Connect Sverige
Skånes mest spännande Life-Science bolag pitchar

Lund, Sweden
November 17, 2017
Connect Sverige

Medicon Valley Alliance
Annual Meeting 2017 – Health, Wealth And World Class

Copenhagen, Denmark
November 10, 2017
Medicon Valley Alliance

BIO-Europe
23RD Annual International
Partnering Conference

Berlin, Germany
November 6–8, 2017

Bio-Europe

BioJapan

Yokohama, Japan
October 11-13, 2017

BioJapan

Nordic Life Science Days

Malmö, Sweden — Copenhagen, Denmark
September 12-14, 2017
nlsdays.com

European Association for the Study of Diabetes

Lisboa, Portugal
September 11-15, 2017
easd.org

Dr. Dorte X. Gram has accepted to give a talk entitled: ‘If I’m right, this could be a really big thing! – daring to challenge status-quo in diabetes treatment’

Prague Summer School – Advances in Drug Discovery
September 4-8, 2017
Prague, Czech Republic
praguesummerschool.cz

San Diego, CA
June 9-13, 2017
the American Diabetes Association’s
77th Scientific Sessions
professional.diabetes.org

San Diego, CA
June 19-22, 2017
The BIO International Convention
convention.bio.org

BioEurope Spring 2017
March 20–22, 2017
CCIB Convention Centre, Barcelona Spain
ebdgroup.com

Next Big Thing, Financial hearing, 2016

Live webcast Next Big Thing from Moderna Museet, Stockholm, Sweden.
December 2nd 2016, 13.00 (UTC/GMT +1 hour)

Almi Invest Seed Day
5 december 2016, Stockholm, Sweden.

PILA PHARMA’s CEO, Dr. Dorte Gram was invited to participate in a company pitch competition amongst 15 of ALMI Invest’s 400 portfolio companies.
Eventregistrering.se

BIO-Europe.

November 7–9, 2016, Cologne, Germany.

  • Lifestyle diseases and longevity
    PILA PHARMA’s CEO, Dr. Dorte Gram was invited to participate as a key speaker in a panel discussion in:
    Day: Monday
    Date: November 7, 2016
    Time: 16:00
    Room: 2 on level 2
  • PILA PHARMA’s company presentation:
    Day: Tuesday
    Date: November 8, 2016
    Time: 17:15
    Room: Rheinsaal 4 on level 2

BIO-Europe.com

Dorte-BIO-Europe

French-Swedish Life Science Day 2016.
October 20, 2016 at the Swedish Embassy, 17 Rue Barbet de Jouy, in Paris.
French-Swedish Life Science Day.eu

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry.
September 14-15, 2016, Stockholm, Sweden.
Nordic Life Science Days.com

Boehringer Partnering Day.
September 13, 2016, Stockholm, Sweden.
bipartnering.com

52nd EASD (European Association for the Study of Diabetes) Annual Meeting.
September 12-16, 2016, Munich, Germany.
easd.org

Anglo-Nordic Lifescience Conference XIII
May 19, 2016 London, United Kingdom
anglonordiclifescience.com

Dansk Bioteks Årsmøde
May 4, 2016 Copenhagen, Denmark
danskbiotek.dk

Bio-Europe Spring 2016
April 4-6 2016, Stockholm, Sweden
ebdgroup.com

10th Swiss-Scandinavian Bio-Business Seminar
February 10, 2016 at SIX Stock Exchange building in Zurich, Switzerland
b2match.eu

Back To Top
Search